CN105617351A - 肽组合物和用于治疗患者的方法 - Google Patents

肽组合物和用于治疗患者的方法 Download PDF

Info

Publication number
CN105617351A
CN105617351A CN201610034403.7A CN201610034403A CN105617351A CN 105617351 A CN105617351 A CN 105617351A CN 201610034403 A CN201610034403 A CN 201610034403A CN 105617351 A CN105617351 A CN 105617351A
Authority
CN
China
Prior art keywords
peptide
compositions
aminoacid sequence
diapin
glucose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610034403.7A
Other languages
English (en)
Chinese (zh)
Inventor
Y·E·陈
C·薛
J·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan (System)
Original Assignee
University of Michigan (System)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan (System) filed Critical University of Michigan (System)
Publication of CN105617351A publication Critical patent/CN105617351A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201610034403.7A 2011-02-11 2012-02-10 肽组合物和用于治疗患者的方法 Pending CN105617351A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161441748P 2011-02-11 2011-02-11
US61/441,748 2011-02-11
CN201280008561.5A CN103458911B (zh) 2011-02-11 2012-02-10 肽组合物和用于治疗患者的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280008561.5A Division CN103458911B (zh) 2011-02-11 2012-02-10 肽组合物和用于治疗患者的方法

Publications (1)

Publication Number Publication Date
CN105617351A true CN105617351A (zh) 2016-06-01

Family

ID=45852697

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610034403.7A Pending CN105617351A (zh) 2011-02-11 2012-02-10 肽组合物和用于治疗患者的方法
CN201280008561.5A Active CN103458911B (zh) 2011-02-11 2012-02-10 肽组合物和用于治疗患者的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280008561.5A Active CN103458911B (zh) 2011-02-11 2012-02-10 肽组合物和用于治疗患者的方法

Country Status (11)

Country Link
US (2) US8664177B2 (cg-RX-API-DMAC7.html)
EP (1) EP2683393B1 (cg-RX-API-DMAC7.html)
JP (3) JP5946473B2 (cg-RX-API-DMAC7.html)
CN (2) CN105617351A (cg-RX-API-DMAC7.html)
AU (1) AU2012214283B2 (cg-RX-API-DMAC7.html)
CA (1) CA2827029C (cg-RX-API-DMAC7.html)
DK (1) DK2683393T3 (cg-RX-API-DMAC7.html)
ES (1) ES2673672T3 (cg-RX-API-DMAC7.html)
HU (1) HUE038787T2 (cg-RX-API-DMAC7.html)
MX (1) MX353301B (cg-RX-API-DMAC7.html)
WO (1) WO2012109561A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2827029C (en) 2011-02-11 2019-07-02 The Regents Of The University Of Michigan Tripeptide compositions and methods
US9456916B2 (en) 2013-03-12 2016-10-04 Medibotics Llc Device for selectively reducing absorption of unhealthy food
US9067070B2 (en) 2013-03-12 2015-06-30 Medibotics Llc Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type
US9011365B2 (en) 2013-03-12 2015-04-21 Medibotics Llc Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food
US20180074053A1 (en) * 2015-04-03 2018-03-15 Zhongmin Ma Treatment of diabetes using agonists of the mas-related gpcr d
KR101909052B1 (ko) 2017-02-09 2018-10-17 강원대학교산학협력단 인슐린의 a 사슬로부터 유래된 펩타이드 단편 및 이를 포함하는 당뇨병 또는 당뇨병성 창상의 예방 또는 치료용 약학 조성물
WO2018237010A2 (en) 2017-06-20 2018-12-27 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Vaccine compositions and methods of using the same
JP7068942B2 (ja) * 2018-06-25 2022-05-17 サンスター株式会社 トリペプチド含有組成物
BR112021002207A2 (pt) * 2018-08-10 2021-05-04 Diapin Therapeutics, Llc tri-peptídeos e tratamento de distúrbios metabólicos, cardiovasculares e inflamatórios
EP4199895A4 (en) * 2020-08-18 2024-11-20 The Regents of The University of Michigan N-ACYL AMINO ACID PRODUCTS AND THEIR USES
CN115252758B (zh) * 2022-08-16 2026-07-17 中国科学院南海海洋研究所 线性小分子肽类似物在制备抗肥胖和降糖药物中应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045941A1 (en) * 1998-03-13 1999-09-16 Mrs, Llc Peptide compositions and formulations and use of same
WO2003024995A1 (en) * 2001-09-19 2003-03-27 Tripep Ab Molecules that block viral infectivity and methods of use thereof
EP2047848A1 (en) * 2006-07-05 2009-04-15 The University of Tokyo Method of treating genetic disease caused by nonsense mutation
WO2011010769A1 (ko) * 2009-07-23 2011-01-27 월드웨이(주) 실크 펩타이드를 유효성분으로 하는 당뇨 치료 또는 예방용 조성물

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL275394A (cg-RX-API-DMAC7.html) 1961-02-28
AU426743B2 (en) 1967-09-21 1972-07-21 MONASH UNIVERSITY, and ICI AUSTRALIA LIMITED Processes forthe production of peptides and proteins
GB8500209D0 (en) 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
JPH04149139A (ja) * 1990-10-12 1992-05-22 Nippon Steel Corp 血糖降下剤
SE520392C2 (sv) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
AU5014500A (en) 1999-05-12 2000-11-21 Board Of Regents For Oklahoma State University, The Reagent and process for peptide/protein differentiation using circular dichroism detection
NZ523403A (en) 2000-05-30 2005-04-29 Connective Tissue Imagineering Compounds that increase tissue elasticity and turgor which are analogous to portions of elastin
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
DE60142840D1 (de) 2000-09-08 2010-09-30 Univ Texas Durch phagendisplay identifizierte zielpeptide des menschen und der maus
AU2001288914A1 (en) 2000-09-08 2002-03-22 Board Of Regents, The University Of Texas System Biopanning and rapid analysis of selective interactive ligands (brasil)
GB0022342D0 (en) 2000-09-12 2000-10-25 Creative Peptides Sweden Ab Reduction of the electrocardiographic QT interval
FI114710B (fi) * 2001-03-12 2004-12-15 Ctt Cancer Targeting Tech Oy Leukosyytti-integriinien uusia peptidiligandeja
EP1497314A4 (en) 2001-09-07 2007-10-10 Univ Texas COMPOSITIONS AND METHODS OF USE ON PEPTIDES AGAINST PLACENTA AND FAT FABRICS
WO2003035028A1 (en) 2001-10-19 2003-05-01 Nektar Therapeutics Modulating charge density to produce improvements in the characteristics of spray-dried proteins
GB0218970D0 (en) 2002-08-14 2002-09-25 Creative Peptides Sweden Ab Fragments of Insulin c-peptide
CA2555841A1 (en) 2004-02-12 2005-09-01 Nektar Therapeutics Interleukin-13 antagonist powders, spray-dried particles, and methods
WO2005115457A2 (en) 2004-05-10 2005-12-08 University Of Utah Research Foundation Combined active and passive targeting of biologically active agents
WO2007046818A2 (en) 2004-11-16 2007-04-26 Board Of Regents, The University Of Texas System Compositions and methods related to synchronous selection of homing peptides for multiple tissues by in vivo phage display
WO2006108211A1 (en) 2005-02-25 2006-10-19 The Murdoch Childrens Research Institute Fragments of von willebrand factor a-related protein
GB0511269D0 (en) 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
GB0601950D0 (en) 2006-01-31 2006-03-15 Creative Peptides Sweden Ab Compositions and methods of treating diabetes
US20090092660A1 (en) 2006-08-09 2009-04-09 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of particles
CZ2006592A3 (cs) 2006-09-18 2008-03-19 Zentiva, A. S. Polymerní lécivo a zpusob jeho výroby
WO2009026614A1 (en) * 2007-08-24 2009-03-05 Dia-B Tech Limited Hypoglycaemic tripeptide and methods of use thereof
CA2827029C (en) 2011-02-11 2019-07-02 The Regents Of The University Of Michigan Tripeptide compositions and methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045941A1 (en) * 1998-03-13 1999-09-16 Mrs, Llc Peptide compositions and formulations and use of same
WO2003024995A1 (en) * 2001-09-19 2003-03-27 Tripep Ab Molecules that block viral infectivity and methods of use thereof
EP2047848A1 (en) * 2006-07-05 2009-04-15 The University of Tokyo Method of treating genetic disease caused by nonsense mutation
WO2011010769A1 (ko) * 2009-07-23 2011-01-27 월드웨이(주) 실크 펩타이드를 유효성분으로 하는 당뇨 치료 또는 예방용 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ERKKI KOIVUNEN等: "Inhibition of β2 Integrin–mediated Leukocyte Cell Adhesion by Leucine–Leucine–Glycine Motif–containing Peptides", 《THE JOURNAL OF CELL BIOLOGY》 *
GANNON MARY C ET AL: "Amino Acid ingestion and glucose metabolism-a review", 《IUBMB LIE》 *

Also Published As

Publication number Publication date
US9062093B2 (en) 2015-06-23
HUE038787T2 (hu) 2018-11-28
JP2016179992A (ja) 2016-10-13
JP5946473B2 (ja) 2016-07-06
WO2012109561A2 (en) 2012-08-16
EP2683393B1 (en) 2018-04-11
US20120208748A1 (en) 2012-08-16
DK2683393T3 (en) 2018-07-23
CN103458911A (zh) 2013-12-18
AU2012214283B2 (en) 2016-01-28
US20140148382A1 (en) 2014-05-29
CN103458911B (zh) 2016-02-24
MX2013009223A (es) 2014-01-23
JP2018131446A (ja) 2018-08-23
CA2827029A1 (en) 2012-08-16
CA2827029C (en) 2019-07-02
AU2012214283A1 (en) 2013-08-29
NZ719672A (en) 2018-12-21
WO2012109561A3 (en) 2013-01-17
MX353301B (es) 2018-01-08
US8664177B2 (en) 2014-03-04
JP6412897B2 (ja) 2018-10-24
NZ614080A (en) 2016-05-27
ES2673672T3 (es) 2018-06-25
JP2014506579A (ja) 2014-03-17
EP2683393A2 (en) 2014-01-15

Similar Documents

Publication Publication Date Title
CN103458911B (zh) 肽组合物和用于治疗患者的方法
RU2546520C2 (ru) Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
JP2005516968A (ja) Ｇｌｐ−１化合物と糖尿病後期合併症モジュレーターの組み合わせ使用
JP2017537894A (ja) Ｇｌｐ−１ｒおよびｇｌｐ−２ｒ二重アゴニスト活性を有する組成物及びペプチド
CA3073011C (en) Acylated oxyntomodulin peptide analog
DK2900230T3 (en) RELATIONSHIPS FOR TREATING ADIPOSITAS AND PROCEDURES FOR USING THEREOF
JP2001500893A (ja) インスリンｃ―ペプチド
US20210401880A1 (en) Pharmaceutical Composition For Preventing Or Treating Obesity, Containing CYCLO(HIS-PRO) As Active Ingredient
CA3091729A1 (en) Glp-1 composition for treating obesity and weight management
EP3653639B1 (en) Polypeptide and composition thereof for treating diseases of metabolic system
AU2004204353A1 (en) Pharmaceutical combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases
US20130296226A1 (en) Methods and compositions for the treatment of metabolic disorders
NZ614080B2 (en) Tripeptide compositions and methods for treatment of diabetes
HK1193563A (en) Tripeptide compositions and their use for treatment of diabetes
HK1193563B (en) Tripeptide compositions and their use for treatment of diabetes
NZ719672B2 (en) Tripeptide compositions and methods for treatment of diabetes
RU2834226C2 (ru) Композиция glp-1 для лечения ожирения и регулирования веса
WO2024261076A1 (en) Weight loss
US20070049535A1 (en) Preventive/remedy for diabetic complications using oligopeptide

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160601